Truist Financial Corp Reduces Holdings in Hologic, Inc. $HOLX

Key Points

• Truist Financial Corp reduced its holdings in Hologic, Inc. by 12.3%, now owning 79,351 shares valued at approximately $5.17 million.
• Hologic reported a quarterly earnings per share (EPS) of $1.08, exceeding analyst expectations, with revenue of $1.02 billion, a 1.2% year-over-year increase.
• Several analyst firms have revised price targets for Hologic, with Citigroup upgrading their rating from "neutral" to "buy" and setting a new price target of $80.00.

Truist Financial Corp decreased its position in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 12.3% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 79,351 shares of the medical equipment provider's stock after selling 11,094 shares during the quarter. Truist Financial Corp's holdings in Hologic were worth $5,170,000 as of its most recent filing with the SEC.

Other hedge funds also recently made changes to their positions in the company. Farther Finance Advisors LLC grew its holdings in shares of Hologic by 22.3% during the first quarter. Farther Finance Advisors LLC now owns 1,835 shares of the medical equipment provider's stock worth $113,000 after purchasing an additional 335 shares during the last quarter. United Services Automobile Association purchased a new position in shares of Hologic during the first quarter worth about $347,000. SG Americas Securities LLC grew its holdings in shares of Hologic by 116.6% during the first quarter. SG Americas Securities LLC now owns 9,609 shares of the medical equipment provider's stock worth $594,000 after buying an additional 5,172 shares during the last quarter. Dynamic Technology Lab Private Ltd purchased a new position in shares of Hologic during the first quarter worth about $641,000. Finally, Cambridge Investment Research Advisors Inc. grew its holdings in shares of Hologic by 1.7% during the first quarter. Cambridge Investment Research Advisors Inc. now owns 32,056 shares of the medical equipment provider's stock worth $1,980,000 after buying an additional 528 shares during the last quarter. Hedge funds and other institutional investors own 94.73% of the company's stock.

Hologic Price Performance

HOLX stock opened at $67.73 on Wednesday. The firm has a 50 day moving average of $67.03 and a 200-day moving average of $63.18. Hologic, Inc. has a 12-month low of $51.90 and a 12-month high of $84.39. The company has a current ratio of 3.55, a quick ratio of 2.81 and a debt-to-equity ratio of 0.52. The company has a market cap of $15.06 billion, a price-to-earnings ratio of 28.10, a PEG ratio of 2.31 and a beta of 0.63.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its quarterly earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.05 by $0.03. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The company had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.01 billion. During the same period last year, the firm earned $1.06 EPS. The company's revenue for the quarter was up 1.2% on a year-over-year basis. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. As a group, equities analysts expect that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Insider Activity

In related news, CEO Stephen P. Macmillan sold 138,358 shares of Hologic stock in a transaction that occurred on Monday, September 22nd. The stock was sold at an average price of $66.97, for a total transaction of $9,265,835.26. Following the completion of the transaction, the chief executive officer directly owned 1,234,624 shares in the company, valued at $82,682,769.28. The trade was a 10.08% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 1.88% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

HOLX has been the topic of a number of research reports. UBS Group raised their price target on Hologic from $65.00 to $70.00 and gave the stock a "neutral" rating in a report on Thursday, July 31st. Weiss Ratings reissued a "hold (c-)" rating on shares of Hologic in a report on Saturday, September 27th. Citigroup raised Hologic from a "neutral" rating to a "buy" rating and raised their price target for the stock from $60.00 to $80.00 in a report on Wednesday, July 9th. Mizuho set a $75.00 price target on Hologic in a report on Thursday, July 31st. Finally, Stephens reissued an "overweight" rating and set a $78.00 price target on shares of Hologic in a report on Thursday, September 18th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and eight have given a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $80.15.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.